摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate | 102409-49-4

中文名称
——
中文别名
——
英文名称
11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate
英文别名
3,9-Epoxy-3H-azirino(2,3-c)(1)benzazocine-5-carboxaldehyde, 1-acetyl-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,9,9a-hexahydro-7,9-dihydroxy-;(11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-8-yl)methyl carbamate
11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate化学式
CAS
102409-49-4
化学式
C16H17N3O7
mdl
——
分子量
363.327
InChiKey
GBDZIDKLGSDRFT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    142
  • 氢给体数:
    3
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamatepotassium carbonate 作用下, 以 甲醇氯仿丙酮碘甲烷 为溶剂, 生成 11-acetyl-4-formyl-9-hydroxy-6-methoxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate
    参考文献:
    名称:
    Method of treating tumors using tetracyclo compounds
    摘要:
    本发明涉及一种治疗哺乳动物的癌症或肉瘤肿瘤的方法,该方法包括向该哺乳动物施用公式为:##STR1##的四环素化合物的有效量,其中R.sup.1是甲酰基,受保护的甲酰基,羟甲基,受保护的羟甲基,芳基氨甲基,羧基,受保护的羧基,芳基亚胺甲基,羟基亚胺甲基,烷氧基亚胺甲基,酰氧基亚胺甲基,半胱氨酸甲基或芳基半胱氨酸甲基,R.sup.2是羟基,烷氧基或受保护的羟基,R.sup.3是氢,R.sup.4是甲基,羟甲基或受保护的羟甲基,或R.sup.3和R.sup.4结合在一起形成亚甲基或氧代亚甲基,R.sup.5是羟基,烷氧基或受保护的羟基,R.sup.6是氢,亚氨基保护基或烷基,以及其药学上可接受的盐。
    公开号:
    US04861774A1
  • 作为产物:
    参考文献:
    名称:
    Method of treating tumors using tetracyclo compounds
    摘要:
    本发明涉及一种治疗哺乳动物的癌症或肉瘤肿瘤的方法,该方法包括向该哺乳动物施用公式为:##STR1##的四环素化合物的有效量,其中R.sup.1是甲酰基,受保护的甲酰基,羟甲基,受保护的羟甲基,芳基氨甲基,羧基,受保护的羧基,芳基亚胺甲基,羟基亚胺甲基,烷氧基亚胺甲基,酰氧基亚胺甲基,半胱氨酸甲基或芳基半胱氨酸甲基,R.sup.2是羟基,烷氧基或受保护的羟基,R.sup.3是氢,R.sup.4是甲基,羟甲基或受保护的羟甲基,或R.sup.3和R.sup.4结合在一起形成亚甲基或氧代亚甲基,R.sup.5是羟基,烷氧基或受保护的羟基,R.sup.6是氢,亚氨基保护基或烷基,以及其药学上可接受的盐。
    公开号:
    US04861774A1
点击查看最新优质反应信息

文献信息

  • Tetracyclo compounds and a pharmaceutical composition containing the same
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04645765A1
    公开(公告)日:1987-02-24
    New tetracyclo compounds of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy or substituted iminomethyl, R.sup.2 is hydroxy, alkoxy or protected hydroxy, R.sup.3 is hydrogen and R.sup.4 is methyl, hydroxymethyl or protected hydroxymethyl, or R.sup.3 and R.sup.4 are combined together to form methylene or oxo, R.sup.5 is hydroxy, alkoxy or protected hydroxy, and R.sup.6 is hydrogen, imino-protective group or alkyl, and pharmaceutically acceptable salts thereof, which have pharmacological activities such as antitumor activity, antimicrobial activity, and the like, and a process for their production and a pharmaceutical composition containing the same.
    新的四环四氮化合物的化学式如下:##STR1## 其中,R.sup.1为甲酰基,保护甲酰基,羟甲基,保护羟甲基,芳基氨甲基,羧基,保护羧基或取代亚胺基甲基;R.sup.2为羟基,烷氧基或保护羟基;R.sup.3为氢;R.sup.4为甲基,羟甲基或保护羟甲基,或者R.sup.3和R.sup.4结合形成亚甲基或氧代亚甲基;R.sup.5为羟基,烷氧基或保护羟基;R.sup.6为氢,亚胺保护基或烷基。这些化合物及其药物可接受的盐具有抗肿瘤活性、抗微生物活性等药理活性。同时,还提供了其制备方法和含有该化合物的制药组合物。
  • Biologically pure culture of Streptomyces sandaensis No. 6897
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04743555A1
    公开(公告)日:1988-05-10
    A biologically pure culture of Streptomyces sandaensis which is capable of producing an antitumor and antimicrobial compound, designated FR-900482 substance, is disclosed.
    本文披露了一种能够产生抗肿瘤和抗微生物化合物FR-900482的Streptomyces sandaensis的生物纯培养物。
  • KOSAKA, MASANOBU;TEHRANO, XIROSI;IVAMI, MORITA;YAMASITA, MITIO;XASIMOTO, +
    作者:KOSAKA, MASANOBU、TEHRANO, XIROSI、IVAMI, MORITA、YAMASITA, MITIO、XASIMOTO, +
    DOI:——
    日期:——
  • Method of treating tumors using tetracyclo compounds
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04861774A1
    公开(公告)日:1989-08-29
    The invention relates to a method for treatment of carcinoma or sarcoma tumor in mammals which comprises administering to said mammal an effective amount of a tetracyclo compound of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy, aryliminomethyl, hydroxyiminomethyl, alkoxyiminomethyl, acyloxyiminomethyl, semicarbazonomethyl or arylsemicarbazonomethyl, R.sup.2 is hydroxy, alkoxy, or protected hydroxy, R.sup.3 is hydrogen and R.sup.4 is methyl, hydroxymethyl or protected hydroxymethyl, or R.sup.3 and R.sup.4 are combined together to form methylene or oxo, R.sup.5 is hydroxy, alkoxy or protected hydroxy, and R.sup.6 is hydrogen, imino-protective group or alkyl, and pharmaceutically acceptable salts thereof.
    本发明涉及一种治疗哺乳动物的癌症或肉瘤肿瘤的方法,该方法包括向该哺乳动物施用公式为:##STR1##的四环素化合物的有效量,其中R.sup.1是甲酰基,受保护的甲酰基,羟甲基,受保护的羟甲基,芳基氨甲基,羧基,受保护的羧基,芳基亚胺甲基,羟基亚胺甲基,烷氧基亚胺甲基,酰氧基亚胺甲基,半胱氨酸甲基或芳基半胱氨酸甲基,R.sup.2是羟基,烷氧基或受保护的羟基,R.sup.3是氢,R.sup.4是甲基,羟甲基或受保护的羟甲基,或R.sup.3和R.sup.4结合在一起形成亚甲基或氧代亚甲基,R.sup.5是羟基,烷氧基或受保护的羟基,R.sup.6是氢,亚氨基保护基或烷基,以及其药学上可接受的盐。
查看更多

同类化合物

氨甲酸(1aS,8R,9aS)-5-甲酰基-7,9-二羟基-3,9-环氧-2,3,8,9,9a,9b-六氢-1H-吖丙因并[2,3-c][1]苯并吖辛因-8-基甲基酯 1-乙酰基-7,9-二(乙酰氧基)-8-(((氨基羰基)氧基)甲基)-1,1a,2,8,9,9a-六氢-3,9-环氧-3H-氮丙啶并(2,3-c)(1)苯并氮杂环辛四烯-5-甲醛 (1aS,3S,8R,9S,9aS)-1-乙酰基-7,9-二(乙酰氧基)-8-(((氨基羰基)氧基)甲基)-1,1a,2,8,9,9a-六氢-3,9-环氧-3H-氮丙啶并(2,3-c)苯并氮杂环辛四烯-5-甲醛 Antibiotic FR 900482 6-(4-methyl-thiazol-2-yl)-dibenzo[d,f][1,3]diazepine-5,7-diol 11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate 1-tert-butyl-2,1-benzisoxazoline 1-methyl-3-morpholin-4-yl-1,3-dihydro-benzo[c]isoxazole 7-Ethyl-3-methyl-1,3-dihydro-2,1-benzoxazole methyl (4aR,10aS,11aS,11bS)-4,4a,10,10a,11,11b-hexahydro-11-(tert-butyloxycarbonyl)-4a-formyl-5-hydroxy-2,2-dimethyl-9,11b-epoxyazirino[2,3-c]-1,3-dioxino[4,5-e][1]benzazocine-7-carboxylate methyl (1aS,8R,9S,9aS)-1,1a,2,8,9,9a-hexahydro-1-(tert-butyloxycarbonyl)-8-formyl-7,9-dihydroxy-8-(hydroxymethyl)-3,9-epoxy-3H-azirino[2,3-c][1]benzazocin-5-carboxylate (1aS,3R,8R,9R,9aS)-dimethyl ester 8-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,1a,2,8,9,9a-hexahydro-9-hydroxy-7-(methoxymethoxy)-3,9-epoxy-3H-azirino[2,3-c][1]benzazocine-1,5-dicarboxylic acid methyl (4R,6R)-2-(2-methoxypropan-2-yloxy)-7-oxo-10-phenylmethoxy-5-oxa-2-azatricyclo[7.4.0.04,6]trideca-1(9),10,12-triene-12-carboxylate FR66979 (+)-FR900482 [(1S,6R,15S,16R)-15-azido-10-(hydroxymethyl)-3-oxo-8-phenylmethoxy-2,4,17-trioxa-13-azatetracyclo[11.3.1.01,6.07,12]heptadeca-7(12),8,10-trien-16-yl] methanesulfonate 4-hydroxylamino-1,1,2,2,9,9,10,10-octafluoro[2.2]paracyclophane 4',7-dichlorospiro[1H-2,1-benzoxazole-3,3'-1H-pyrrole]-2'-one 11-O'-tert-butyl 4-O'-methyl (4S,9'R,10'S,12'S)-6',9'-dihydroxy-2-oxospiro[1,3-dioxolane-4,8'-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-triene]-4',11'-dicarboxylate 1-tert-Butyl-2,1-benzisoxazolin-3-ol (+)-FR900482 7-epi-(+)-FR900482 11-O-tert-butyl 4-O-methyl (8S,9R,10S,12S)-6,9-dihydroxy-8-(hydroxymethyl)-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-triene-4,11-dicarboxylate methyl (4R,6R,7S)-2-hydroxy-10-phenylmethoxy-7-tri(propan-2-yl)silyloxy-5-oxa-2-azatricyclo[7.4.0.04,6]trideca-1(9),10,12-triene-12-carboxylate (1,4-dihydroxy-3-iminoquinoxalin-2-ylidene)-nitrosomethanamine 2-(1H-2,1-benzoxazol-3-ylidene)-5-methylimidazole-4-carboxylic acid 4-Hydroxy-1-oxo-2,3-dihydro-1,2,4-benzotriazin-1-ium-3-amine N-[1H-2,1-benzoxazol-3-ylidene(nitroso)methyl]-3-chloro-4-fluoroaniline 4-hydroxy-6-methyl-3H-1,2,4-benzotriazin-3-amine 1,4-dihydroxy-3-imino-2H-quinoxaline-2,5,8-triamine N-(11-amino-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl)hydroxylamine;ethane 2-[[4-(3-chlorophenyl)-1H-2,1-benzoxazol-3-ylidene]methyl]-5-methyl-N-[2-(triazol-1-yl)ethyl]-1H-pyrrole-3-carboxamide 1-(1H-2,1-benzoxazol-3-ylidene)-N-[(2-methylphenyl)methyl]-1-nitrosomethanamine 6-Methyl-5,7-dihydroxy-6,7-dihydro-5H-dibenzo<1,3>diazepin 6-ethyl-dibenzo[d,f][1,3]diazepine-5,7-diol 2-(3H-Benzo[c]isoxazol-1-ylmethyl)-malononitrile 1,4-di-N-oxide-3-amino-2-imidazolequinoxaline. (1S,6R,15S,17S)-10-(dimethoxymethyl)-8-phenylmethoxy-2,4,18-trioxa-13,16-diazapentacyclo[11.4.1.01,6.07,12.015,17]octadeca-7(12),8,10-trien-3-one (+)-FR66979 4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate 6,9-dihydroxy-4-hydroxymethyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate methyl N-[(1-hydroxy-4-oxido-3,4-dihydroquinoxalin-4-ium-2-ylidene)methylimino]carbamate 1,4-Dihydroxy-2,3-dihydroquinoxaline methyl N-[(1,4-dihydroxy-2,3-dihydroquinoxalin-2-yl)methylideneamino]carbamate